PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in...

Read more

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially submitted a draft registration statement on Form S-1...

Read more

DOWNLOAD PRESENTATION

Read more

Complete Enrollment of Phase 2 Trial to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects with Lumbosacral Radiculopathy, a.k.a. sciatica All subjects experienced rapid reduction of...

Read more

Semnur’s SP102, addressing multi-billion dollar unmet market needs, in Pivotal Phase 3 Trial with Fast Track Status from the FDA With non-opioid ZTlido, RTX, and SP102 commercial and near-commercial product lines, Sorrento and its subsidiaries...

Read more

SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8%...

Read more

SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that ZTlido® (lidocaine topical system) 1.8% (ZTLIDO) is covered by...

Read more

SAN DIEGO, September 19, 2018 – Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO)...

Read more

Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles Pain SAN DIEGO, September 7, 2018 – Scilex Pharmaceuticals...

Read more

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U.S. Food and Drug Administration (FDA) for ZTlido™...

Read more